PCI 7 November 2023, 15:22
Thermofisher: Thu 29 February 2024, 11:15
BMG Labtech: Wed 18 September 2024, 11:55
Owen Mumford 12 January 2022, 16:46

Current Edition

Cell and Gene Therapy

Upcoming Events

PEGS Boston – 17/02/2025
NextGen BioMed – 04/02/2025
BioTrinity 2025 – January 30th 2025
Elrig R&I 2025 – 27th January 2025
Biotechnology Show 2025: 20th January 2025
Anglonordic: 16th January 2025
AI in Drug Discovery – SAE media – January 14th 2025

Advertisement

Fujifilm rectangle: Fri 22 November 2024, 14:23
Roald Dahl Charity: Fri 15 November 2024, 12:57
A&M STABTEST: Fri 21 June 2024, 11:43
CDD Vault: Wed 17 July 2024, 11:46
Aurisco – 04/02/2025

Sanofi, GSK say COVID vaccine works as booster, but delay key study results

Sanofi and GSK expected to have definitive results for their long-delayed coronavirus vaccine by now, having redesigned their shot after an initial formulation disappointed late last year.

A verdict on whether their revamped vaccine can match the effectiveness of other vaccines in preventing COVID-19 is likely coming soon, with the companies indicating the trial will continue into “early 2022.” But results will have to be particularly strong for the shot to be used in countries with ready supplies of others from Pfizer, Moderna, Johnson & Johnson and AstraZeneca.

Complicating matters further is the omicron variant, which appears likely to at least partially escape the protection provided by available vaccines. (Much of the preliminary data now available is focused on Pfizer’s vaccine, and booster doses seem to offer strengthened immunity even against omicron.)

Should Sanofi and GSK’s vaccine prove effective against COVID-19, the results released Wednesday may help position the shot as a potential booster dose, particularly in areas with less supply of other vaccines.

The small study, which enrolled a little over 500 participants, tested one dose of the companies’ protein-based vaccine four to 10 months after the volunteers had received an approved primary series of Pfizer, Moderna, J&J or AstraZeneca’s shots.

Participants were enrolled across the U.S., U.K. and France and the trial is continuing to assess other vaccine formulations targeting the beta coronavirus variant. More data could come in the first half of next year, although the companies noted that omicron was not circulating during the trial.

Instead, Sanofi and GSK are using blood samples from booster dose participants to measure how much their vaccine can help in neutralizing omicron.

But the companies’ booster dose data will mean little until results are available from the larger Phase 3 trial, which began in late May and has enrolled more than 10,000 participants across its first stage. A second phase is evaluating a tweak on the companies’ formulation to incorporate targeting of the beta variant, which shares some of the mutations found on omicron.

An independent committee monitoring the trial recommended it continue so more data could be collected, particularly in people who have not been previously infected by the coronavirus. That became a harder task in the later summer and fall, when the delta variant spurred waves of infections in many countries.

The committee identified no safety concerns, Sanofi and GSK said.

Newcells 3 June 2024, 15:12
Novonordisk: Wed 17 July 2024, 11:22
FujiFilm 30 October 2023, 16:23
Autoscribe Mon 26 June 2023, 15:15
Aldevron: 16th January 2025
Richter: Wed 23 October 2024, 09:03
GenXPro: Mon 16 September 2024, 10:40